The pharmacological profile of KR-31081, a newly synthesized AT1 receptor antagonist, was evaluated in pithed rats, conscious renal hypertensive rats (RHRs) and conscious furosemide-treated beagle dogs. In pithed rats, KR-31081 (i.v.) induced a non-parallel right shift in the dose-pressor response curve to angiotensin II (ID50: 0.05 mg/kg) with a dose-dependent reduction in the maximum responses; this antagonistic effect was about 40 times more potent than losartan (ID50: 1.74 mg/kg) which showed competitive antagonism. KR-31081 did not alter the responses induced by other agonists such as norepinephrine and vasopressin. In RHRs, orally given KR-31081 produced a dose-dependent and long-lasting (>24 h) antihypertensive effect with a higher potency to losartan (ED20: 0.30 and 3.36 mg/kg, respectively). In furosemide-treated dogs, orally given KR-31081 produced a dose-dependent and long-lasting (>8h) antihypertensive effect with a rapid onset of action (time to Emax: 1-1.5 h) and 20-fold greater potency than losartan (ED20: 0.41 and 8.13 mg/kg, respectively). These results suggest that KR-31081 is a potent, orally active AT1 receptor antagonist useful for the research and diagnostic tools as an added exploratory potential.
Introduction
It is well known that the major pharmacologic actions of angiotensin II (AII), such as contraction of vascular smooth muscle, aldosterone release from the adrenal gland, and cell proliferation and hypertrophy of cardiovascular tissues, are mediated by the AT1 subtype [1, 2] . Therefore, AII receptor antagonists with selectivity for the AT1 subtype are considered to be useful for the treatment of patients with hypertension accompanying cardiac hypertrophy and vascular thickening. Since the discovery of losartan, the first drug developed and marketed as an AT1 receptor antagonist [3, 4] , a growing number of angiotensin receptor antagonists have been introduced. A numerous studies have reported that losartan is an orally active competitive AII receptor antagonist with selectivity for AT1 subtype in animals [5, 6] and humans [7, 8] . Losartan and its metabolite EXP3174 have been reported to antagonize AII in different ways, showing surmountable and insurmountable antagonism, respectively [4, 9] .
Recently, the application of AII receptor antagonists has expanded to ongoing trials for noninvasive diagnostics as in positron emission tomography imaging [10] [11] [12] , therefore upcoming AT1 receptor antagonist candidates are important developments as new diagnostic tools in future.
In the present study, the pharmacological profile of KR-31081 was examined in various in vivo systems including pithed rats, conscious renal hypertensive rats (RHRs), and conscious furosemide-treated dogs. [4,5-b] pyridine, US patent #5691348) and losartan [3] were synthesized at the Bio-Organic Science Division, KRICT, and were dissolved in 0.05 N KOH in saline and 
Materials and Methods

Chemicals
KR-31081(2-butyl-5-dimethoxymethyl-6-(pyridyn-2-yl) -3-[[2'-(1H-tetrazol-5-yl)biphenyl -4-yl]methyl]-3H-imidazo
In vivo potency and specificity as AII antagonist in pithed rats
Male Sprague-Dawley rats (350-450 g, KRICT) were anesthetized with sodium pentobarbital (35 mg/kg, i.p.).
After a tracheotomy was performed, artificial ventilation with room air was initiated with rodent ventilator (model 7025, Ugo Basile, Varese, Italy; frequency: 60 cycles/min; stroke volume: 1 ml/100 g body weight). Two polyethylene (PE-50) catheters connected to catheter that were filled with heparinized saline solution (20 IU/ml) were inserted into the left femoral artery and vein for recording arterial blood pressure and drug administration, respectively. The arterial catheter was connected to an Isotec pressure transducer (Healthdyne, Georgia, U.S.A.) coupled to a Graphtec Linearcorder (model 3310, Graphtec Corp., Japan). Subsequently, the animals were pithed by inserting and driving a steel rod (2 mm in diameter) via the orbit and the foramen magnum down into the whole length of the spinal canal [13] . The animals were kept warm at 37°C by means of a thermostat-controlled heating pad. Arterial blood pressure and heart rate were continuously recorded through the whole experiment. 
Antihypertensive effects in conscious RHRs
For preparing RHRs, the left renal artery of 
Antihypertensive effects in furosemide -treated dogs
Statistical analysis
All values are expressed as mean ± S.E.M. Data were analyzed by one-way analysis of variance (ANOVA) followed by the Dunnett's test for multiple comparisons (Sigma Stat, Jandel Co., San Rafael, CA, U.S.A.). In all comparisons, the difference was considered to be statistically significant at p < 0.05.
Results
In vivo potency and specificity of AII antagonist in pithed rats
In pithed rats treated with vehicle (control group) under the experimental conditions used, the mean diastolic arterial pressure was 30.9 ± 4.8 mmHg. 
Antihypertensive effects in conscious RHRs
The effects of the orally administered KR-31081 (0. [8] J. M. Mallion, and A. I. Goldberg, "Global efficacy and tolerability of losartan, an angiotensin II subtype 1-receptor antagonist, in the treatment of hypertension",
